GM2 gangliosidoses are a group of lysosomal storage disorders which include Sandhoff disease and Tay-Sachs disease. Dysregulation of glutamate receptors has been recently postulated in the pathology of Sandhoff disease. Glutamate receptor association with neuronal pentraxins 1 and 2, and the neuronal pentraxin receptor facilitates receptor potentiation and synaptic shaping. In this study, we have observed an upregulation of a novel form of neuronal pentraxin 1 (NP1-38) in the brains of a mouse model of Sandhoff disease and Tay-Sachs disease. In order to determine the impact of NP1 on the pathophysiology of Sandhoff disease mouse models, we have generated an Np1 À/À Hexb À/À double knockout mouse, and observed extended lifespan, improved righting reflex and enhanced body condition relative to Hexb À/À mice, with no effect on gliosis or apoptotic markers in the CNS. Sandhoff mouse brain slices reveals a reduction in AMPA receptor-mediated currents, and increased variability in total glutamate currents in the CA1 region of the hippocampus; Np1
Introduction
The GM2 gangliosidoses are a group of lysosomal storage disorders containing Sandhoff disease (SD) and Tay-Sachs disease (TSD). Both diseases present forms that vary in severity and onset of symptoms, depending on the specific mutations involved. Tay-Sachs disease consists of infantile, juvenile, chronic and late-onset Tay-Sachs disease (LOTS) forms (1) . Sandhoff disease also presents with infantile, juvenile and adult forms of the disease (2, 3) . These diseases present with a plethora of symptoms including cognitive deficits, muscle weakness and ataxia (4, 5) . Late-onset Tay-Sachs disease patients can develop psychiatric symptoms, i.e. schizophrenia-like and bipolar disease-like symptoms (6, 7) .
Sandhoff disease is caused by accumulation of the gangliosides GM2 and GA2 in the central nervous system. This is due to mutations in the Hexb gene, which encodes the beta-subunit of the lysosomal enzymes b-hexosaminidase A and b-hexosaminidase B. Hexb À/À mice are well recognized to represent Sandhoff disease and Tay-Sachs disease. Hexb À/À mice display motorneuronal and behavioural deficits, reaching endpoint at $17-19 weeks (8, 9) . Previous studies on Sandhoff disease have focused on gliosis as a phenomenon common with other neurodegenerative disorders such as Alzheimer's and Parkinson's (10, 11) . Microglial activation appears to precede astroglial activation and is induced via pathways involving C-C chemokine receptor type 2 (CCR2), macrophage-inflammatory protein 1a (MIP-1a), and tumour necrosis factor-a (TNFa) (12) (13) (14) . Astrogliosis, on the other hand, coincides with an increase in caspase-9 activation, suggesting astrocytes may be crucial to the end stages of the disease (15) . Studies have shown that ganglioside accumulation is sufficient to activate astrocytes in SD cells; however, we have also shown a reduction in astrogliosis via knock-out of TNFa in our mouse model, suggesting that cytokine induction is an important factor in astrogliosis at the organismal scale (16, 17) . An increase in secreted TNFa has been shown to cause a release of glutamate from microglia, facilitating excitotoxicity-a neurodegenerative process that involves overstimulation of neurons resulting in toxic levels of intracellular calcium ions (18) . Alterations in glutamate receptors, and an increase in apoptosis, may be indicative of this process as it has been demonstrated that TNFa exposure can stimulate recruitment of the AMPA receptor GluR1 to the cell membrane in dissociated rat hippocampal neurons, as well as inhibit the uptake of synaptic glutamate, enhancing the likelihood of excitotoxicity (19) (20) (21) (22) . The mechanism for this TNFa-induced recruitment of GluR1 is currently unknown, and this could potentially occur through regulation by neuronal pentraxins.
Neuronal pentraxin 1 (NP1) has been indicated as directly involved with activation of an apoptotic pathway in rat cerebellar granule cells, and is involved with AMPA induced neuronal death by GluR1 during hypoxic-ischemic injury in neo-natal rats (23) (24) (25) . Contrarily, neuronal pentraxin complexes, consisting of NP1, neuronal pentraxin 2 (NARP) and the neuronal pentraxin receptor (NPR), could possibly protect from excitotoxicity, via a role in endocytosis of AMPARs. Long-term depression in cerebellar Perkinje cell cultures, and in the hippocampus has be shown to be induced via cleavage of the NPR via the matrix metalloprotease (MMP) tumor necrosis factor-a converting enzyme (TACE) (26) . NP1 has also been suggested to be involved in the elimination of synapses through binding of the complement protein C1q, causing synaptic removal via phagocytosis by glia (27) (28) (29) . Establishing a beneficial or detrimental role for NP1 in Sandhoff disease may open avenues for treatment of neurodegenerative diseases, and point to the study of pathways beyond those established with respect to gliosis.
We observe increased expression of a novel form of NP1 (NP1-38) in our Sandhoff disease mouse model. We also demonstrate increased survival and function of the Sandhoff disease model after knockout of Np1, suggesting that NP1 or its alternative form contributes to disease progression.
Results

Identification of a novel form of NP1
GluR1 expression, known to be under the control of NP1, is downregulated in our Sandhoff disease mouse model near endpoint (15) . In order to detect alterations of NP1 gene expression in lysosomal storage disorders, we compared the expression levels of NP1 mRNA in human TSD cerebellar cells with those of normal human cerebellar cells (Fig. 1A) . We also compared the expression of Np1 mRNA in Hexb À/À mouse cerebellar cells with that in a WT mouse (unpublished data).
There is a significant increase in the mRNA for NP1 in the human TSD cerebellum relative to normal, and in the mouse SD cerebellum relative to WT. This increased expression suggests that neuronal pentraxin 1 is involved in lysosomal storage disorders. We then performed western blots to determine the temporal expression of NP1 protein in the cerebellum of our WT and Hexb À/À mice. No changes in the expression of $50 kDa NP1 were found, relative to controls (Fig. 1B) . However, we observed a $38 kDa band that was upregulated in the SD mice as early as 60 days of age (currently labeled with the tentative name NP1-38) ( Figs 1C and 2A) . Inquiry into whether both are forms of NP1 is warranted as discovery of an unexplored regulatory form of neuronal pentraxin 1 could provide great insight into synaptic regulation and disease. To this end, we crossed Hexb À/À and Np1 À/À mice, both on a C57BL/6 background, to obtain Np1
double-knockout (DKO) mice. Indeed, the 38-kDa band is absent from the DKO mice, confirming that the 38-kDA form is a product of the Np1 gene ( Fig. 2B and C). Immunoprecipitation with an anti-NP1 antibody isolates two bands in Hexb À/À mice-at 50 kDa and 38 kDa-that are absent from Np1 À/À Hexb À/À mice (Fig. 2B ).
Both forms are able to bind the antibody under non-denaturing conditions, suggesting that there are no large conformational changes in the 38-kDa protein, at least in the antibody-binding region towards the centre of the primary amino-acid sequence (Rat NP1, aa.137-312). NP1 is known to be N-glycosylated, so WT, SD, and DKO cerebellar lysates were treated with N-glycosidase F, and it was found that both the 50-kDa and the 38-kDa bands are equally shifted by $10 kDa and as a result they appear to be similarly N-glycosylated (Fig. 2C) . Therefore, the 38-kDa protein is likely a truncated form of NP1 that maintains the same glycosylation sites.
Knockout of Np1 improves behaviour and survival of Sandhoff disease mice
Since NP1-38 is upregulated early in the disease, indicating potential contribution of NP1 and/or NP1-38 to disease progression, we sought to elucidate the overall effect of NP1 isoforms on the health and behaviour of (Fig. 4A ).
Once again there appears to be increased variability in the body condition of Np1 À/À Hexb À/À mice towards the expected endpoint.
Markers for gliosis and apoptosis
Since outcomes of Sandhoff disease are widely known to be negatively influenced by astrogliosis and microgliosis, we sought to observe the effect of Np1 knockout on these disease processes. Immunohistochemistry of cerebral cortex, cerebellar, and spinal tissues from 120-day Hexb Hexb À/À mice, suggesting that Np1 is not a major driving factor in these processes in the disease (Fig. 5 ). There is however, a non-significant trend toward lower levels of TUNEL staining in the cerebellum, and cerebral cortex of Np1 . A similar pattern is seen in the cerebellum. These measurements suggest that, between Hexb À/À mice, there is high variability in the relative amount of apoptosis in the end-point stages of the disease.
Knockout of NP1 reduces neuronal dysregulation in Sandhoff disease
Like the cerebellum, the hippocampus is well known to be pathologically affected in Sandhoff disease, presenting with GM2 accumulations, inflammation, apoptosis, impaired dendritic growth, calcium uptake inhibition, and impaired phospholipid production (30) (31) (32) (33) (34) (35) . Since neuronal pentraxins have been shown to be involved in long-term depression through modulation of surface AMPARs in the hippocampus, we sought to observe the effect of NP1 knockout on AMPA and NMDA sensitivity of neurons through patch clamp recording (26) . GABAergic responses were inhibited with the GABAR antagonist picrotoxin, and pyramidal neurons in of the CA1 region of the hippocampus were voltage-clamped at þ40 mV to measure combined AMPAR/ NMDAR currents, and at À60 mV to measure the contribution of AMPAR currents in response to stimulation of the CA3-CA1 pathway. Specificity of the currents was confirmed pharmacologically using the AMPAR and NMDAR antagonists CNQX and D-APV.
Measurements of total currents show a strong trend to differences in variability of current amplitude between groups (Levene's, P ¼ 0.068), suggesting glutamatergic currents are less tightly regulated in Hexb knockout mice than in controls, and that not all Hexb À/À neurons are affected concurrently (Fig. 6A) .
We also observe a trend of reduced amplitude AMPAR-mediated currents in Hexb À/À mice relative to controls (Fig. 6B) . The reduction in AMPAR-mediated currents in Hexb À/À mice is consistent with a reduction in GluR1 expression we have observed in the cerebella of these mice (15) . This may be attributed to either a reduction in the overall number of GluR1 receptors in affected neurons, or perhaps the selective death of GluR1-containing glutamatergic neurons. This reduction in AMPAR-mediated currents may be recovered by knockout of Np1 (ANOVA, P ¼ 0.135). Since NP1 has a negative effect on the survival of Hexb À/À mice, it would seem this loss of AMPARs is detrimental and not a mechanism of protection. AMPRA-mediated currents in Hexb À/À neurons were noticeably reduced at physiologically relevant membrane potentials of À60 mV (Fig. 6C ).
To test whether the observed effects are due to increases or decreases in excitatory protein levels, western blots were performed on hippocampi and cerebella from 30-day-old WT and Hexb À/À mice, for NP1-38, GluR1, and GluR2 ( Fig. 7 ). An increase is seen in the levels of NP1 in the SD hippocampus, though-due to the small effect size-this difference could be present yet undetectable in the cerebellum, and may require a larger sample size to detect. NP1-38 is significantly upregulated for both tissues in SD mice at 30 days ( Fig. 7C /G), while the measured glutamate receptors showed no difference between genotypes ( Fig. 7D and E/ H and I). This indicates that differences in neuronal excitability may be due to differences in subcellular receptor trafficking rather than raw protein increases/decreases, and verifies that absolute levels of GluR1 do not drop until late in the disease.
Discussion
A potentially novel isoform of Np1
The increased expression of NP1 mRNA in Tay-Sachs disease patients, and Np1 mRNA in Sandhoff disease mice strongly suggests a role for their gene products in lysosomal storage disorders-in both humans and mice. This finding also further validates that our Hexb À/À mouse is an accurate representation of human forms of these diseases. The presence of NP1-38 essentially only in the disease state suggests a specific role in either disease progression or prevention. A separation from the more generalized functions of NP1 would make this an interesting target for manipulation, with limited disruption of normal cellular events. Though the role of this protein is currently unknown, identification of its modifications would give immediate clues to its function. Loss of the N-terminal neuronal pentraxin-neuronal pentraxin binding cysteines would point to a role absent NARP and NPR, since they could no longer bind each other. However, loss of the original Nterminal signal sequence would mean that NP1 does not pass through the ER-Golgi pathway, but maintenance of N-glycosylations suggests the N-terminus is not modified, at least until after passage through the Golgi apparatus. At this stage NP1 would already be bound to NARP and NPR via disulphide bonds near the N-terminus, making modification in this region of the protein difficult or ineffective. On the other hand, loss of the C-terminal AMPAR-binding 'pentraxin domain' would indicate a change in the ability to bind one of its canonical binding partners, including GluR1 or BAX (36, 37) . The ability of the protein to bind anti-NP1 antibodies in denatured and non-denatured conditions, suggest that no large modifications or conformational changes occur towards the centre of the protein (the epitope for the antibody used). Together these data suggest that NP1-38 is modified at the C-terminus, leading to changes in its AMPAR binding behaviour (Fig. 8 ).
Np1 reduces survival in Sandhoff disease
Though its precise actions still need to be elucidated, it is clear that Np1 has a negative effect on survivability in Sandhoff disease. As these mice are on the same C57BL/6 background, it is unlikely to be an effect of other genetic differences. This appears to be linked to systems related to the righting reflex, such as the cerebellum, but not to other neuromotor systems. This is surprising, since in many cases of knockout genes improving lifespan, mice improved performance in behaviour testing, including wire hang and rotarod. In these cases, the increases in lifespan were quite large, however; and perhaps any other behavioural improvements in Np1
are too subtle for statistical detection. It is also possible that since the cerebellum is known to be severely affected in the disease, and thus has a high level of cell death, that it is also sensitive/responsive to treatments related to neuronal death (14, 38) .
Effect of Np1 on Hexb À/À neuronal excitation
The observed dysregulation of total currents in the hippocampus of our Sandhoff mice is consistent with reports suggesting an association between dysregulation of the glutamatergic system in the hippocampus and presentation of mood disturbances in patients with bipolar disorder (39, 40) . Since patients with LOTS present with bipolar-like mood disturbances, this may indicative of a common pathophysiology. The apparent recovery of glutamate receptor regulation in our Np1 mouse hippocampi appears to be an effect of the presence of NP1. This is consistent with a reduction of GluR1 we have observed in the cerebellum of Hexb À/À mice towards endpoint (15) .
Since NP1 has a negative effect on the survival of Hexb À/À mice, it would seem this loss of AMPARs is detrimental and not protective. Though we do not see an increase in NP1 levels aside from a slight increase in the hippocampus of Hexb À/À mice at 30 days, we observe a large increase in NP1-38 levels in both the hippocampus and the cerebellum. Both of these brain areas also have similar pathologies involving inflammation, apoptosis, and a late-stage increase in major histocompatibility complex class II molecules (MHC class II), suggesting a common disease mechanism leading to the deterioration of the righting reflex and survival (32) . In rats, NP1 has been shown to upregulate and colocalize with GluR1 in response to hypoxic-ischemic brain injury. This association was also shown to be directly responsible for AMPAR-mediated cell death in mouse hippocampal neurons during hypoxic-ischemic conditions, suggesting excitotoxicity as a cause (36, 41, 42) . On the other hand, in Alzheimer's disease, the build-up of amyloid-b leads to lower synapse activity and ultimately apoptosis of transmitterspecific neurons through a mechanism involving NP1 (43, 44) . Similar effects may be causing the death of excitatory neurons in SD after ganglioside build-up interferes with function of their AMPARs, leading to the decline of glutamate receptors later in life. Other possibilities include that NP1/NP1-38 produced by neurons exposed to TNFa may be recruiting GluR1 to the cell surface, and depleting internal GluR1 stores, or perhaps is regulating GluR1 levels via receptor internalization, or synaptic phagocytosis by microglia-signalled via the complement protein C1q (21, (26) (27) (28) (29) . The internalization of AMPARs, and the involvement of C1q seem unlikely, however, since GluR1 and GluR2 levels do not drop directly in correlation with early NP1-38 increases (15) . Regardless of the underlying mechanism, if NP1 or NP1-38 are causing the dysregulation/death of AMPAR containing neurons, then limiting their expression may be a useful treatment to promote the maintenance of functional neurons.
Although we observe changes in glutamate signalling in the hippocampus of our mice at a very early stage, we do not see a decline in glutamate receptor protein or overall health until near the endpoint of the mice (15) . Thus, the effects of the glutamatergic dysregulation are likely to be chronic and develop over a period of time, and will therefore have a larger effect in chronic/late onset forms of Tay-Sachs and Sandhoff disease.
Effect of Np1 knockout on pathological markers
While no significant differences were found between Np1 À/ À Hexb À/À and Hexb À/À mice in measures of markers for gliosis or apoptosis, this is not entirely unexpected at 120 days of age, where variation in behaviour and protein levels increases, as mice reach endpoint. NP1 has been reported to be present in astrocytes but its level of expression does not change in concordance with a rise in astrogliosis markers, which rise at $100 days (15, 45) . If NP1-38 was being produced inside activated astrocytes, we would expect similar temporal patterns of expression for the two proteins, but this is not the case. Other mouse studies have shown that a detrimental NP1 response to ischemic brain injury does not colocalize directly with astrocytes, which is consistent with these findings (46) . Since the effect of NP1 does not appear to be directly linked to levels of CNS inflammation, this may indicate a separate pathway for treatment, alongside inflammation management systems. Macrophages are activated as early as 60 days in Hexb À/À mice, consistent with increased levels of NP1-38 (15) . Whether NP1-38 is produced by the activated macrophages, or interacts with them though a mediator such as C1q, remains to be investigated. If NP1 is not acting through microglia or astrocytes, it may be increasing apoptosis by affecting the sensitivity of neurons to excitatory stimuli, or enhancing the direct mechanisms of apoptosis, including mitochondrial function.
Conclusions
We have identified a novel form of neuronal pentraxin 1, NP1-38, in Sandhoff disease mice, expressed in several brain regions highly affected by the disease. It is evident that NP1 and/or NP1-38 negatively influence health and survival in Sandhoff disease, apparently through dysregulation of AMPAR function. This dysregulation may play a greater role in chronic and late-onset forms of the disease. Most research into this disease has been focused on inflammation and astrogliosis, but these findings present a new insight and focus on the dysfunction of neurons in Sandhoff disease. The apparent dissociation of this pathway from the inflammatory pathways may allow for concurrent medical interventions alongside those for inflammation, thus increasing potency of treatment.
Methods and Materials
Mice
Mouse work was conducted under an animal utilization protocol (AUP) in accordance with Ontario Animals for Research Act requirements, and the standards of the Canadian Council on Animal Care (CCAC). Hexb À/À mice on a C57BL/6 background were donated generously by Dr R. Gravel (University of Calgary, Calgary, AB, Canada), and have been previously characterized and described (47) . Np1 À/À mice were generated as previously described, on a C57BL/6 background via a PGK-hprt replacement of the signal peptide-bearing exon 1 (48) . These mice are asymptomatic up until at least the normal Hexb 
and Hexb À/À mice were measured at 100 and 120 days of age. Few differences are seen between genotypes at 100 days, but body mass of Hexb À/À mice declines relative to controls at 120 days, while that of Np1 À/À Hexb À/À does not. All data are from female mice, with the following sample sizes (n): 100 days (Hexb 
Cell culture
Normal and TSD cerebellar cells were obtained from Dr S Brooks at the Kingsbrook Jewish Medical Centre in New York. 
Cells were cultured in a 37 C humidified incubator with 21% O 2 and 5% CO 2 and cultured in Dulbecco's modified eagle medium (Invitrogen, #12800017) supplemented with 15% fetal calf serum (Invitrogen, #12483020), 1% penicillin/streptomycin (Invitrogen, #15140122) and 0.1% fungizone (Invitrogen, #15290018).
RNA isolation and reverse transcription
For cell culture, total RNA from confluent cells was isolated by scraping cells in lysis buffer containing 1% b-mercaptoethanol and passing lysate through an 18 1 =2 gauge needle, followed by and purification using the Purelink RNA Isolation Kit (Ambion, #12183018A) or the Total RNA Purification Kit (Norgen, #17200). RNA was reverse transcribed with oligo-dT or random primers according to the Superscript III protocol (Invitrogen Superscript III, #18080-093). RNA, dNTPs, and primers were incubated at 65 C for 5 min, then on ice for 1 min. First strand buffer, DTT, RNase OUT and Superscript III were added to the mixture and incubated at 25 C for 5 min, if random primers were used. Then, the mixture was incubated at 50 C for 1 h and inactivated at 70 C for 15 min.
Quantitative RT-PCR
qRT-PCR was performed on normal and TSD cerebellar cell cDNA, using Taqman gene expression master mix (Applied Biosystems, #4370048). cDNA was mixed with master mix and gene specific probes, and added to a MicroAmp Optical 96-well Reaction Plate (Applied Biosystems, #4316813). The plate was spun down quickly to remove bubbles and placed in the 7900HT Sequence Detection System (Applied Biosystems). Thermal cycling conditions were as follows: 50 C for 2 min, 95 C for 10 min, then 40 cycles of 95 C for 15 s, 60 C for 1 min. A standard curve was used and final values are expressed as relative gene of interest divided by the endogenous control (GAPDH). Primers and probes used were as follows: NPTX1 Hs00159652_m1, and GAPDH Hs99999905_m1 (Applied Biosystems).
Western blot
Western blots were performed on cerebellar lysates from Hexb þ/ þ and Hexb À/À mice at 120 days of age. Mice were perfused via intracardiac injection with PBS, and then cerebella were harvested into microcentifuge tubes, and placed directly into liquid nitrogen. Cerebella were lysed in RIPA buffer (50 mM Tris, 165 mM NaCl, 1% Nonidet P-40, 0.01% sodium dodecyl sulfate, 0.5% Sodium deoxycolate, pH 8.0) containing protease inhibitors, via sonication (Sonicator XL 2020, Heat Systems Inc., Duty 20%, Output 4). Protein was measured using the Bio Rad DC Protein Assay (#500-0116). Samples were diluted to equal protein concentrations with RIPA buffer, and Laemmli sample buffer (6Â) was added. Samples were heated at 65 C for 20 min, and then placed on ice. Samples were run on a 10% SDSpolyacrylamide gel (90 V), and transferred to a nitrocellulose membrane (100 V, 1 h). Membranes were blocked with 5% cow milk (Carnation) in Tris-buffered saline containing 0.5% Tween-20 (TBST), before overnight incubation with mouse primary antibody-anti-NP1 (BD Transduction Labs, #610369) suspended in 5% milk in TBST, at 4 C. After washing in TBST 5 times, membranes were blotted with secondary goat anti-mouse (Santa Cruz Biotechnology, sc-2005) IgG-HRP conjugated antibodies in 5% milk in TBST for 1 h at room temperature, followed by five washes in TBST. Blotted membranes were incubated with Amersham ECL Western Blotting Detection Reagents (GE Healthcare, #RPN2106) and exposed on Amersham Hyperfilm ECL film (GE Healthcare, #28906839). Densitometry was measured using the gel analysis feature in ImageJ (v1.46r, NIH, USA), and normalized to respective GAPDH measurements (R þ D Systems, #AF5718).
Deglycosylation of Np1
Deglycosylation was performed on cerebellar lysates from 120-day-old female wild-type, Hexb 
Immunoprecipitation of Np1
Cerebella from Hexb À/À and Hexb À/À Np1 À/À mice were lysed via sonication on ice, in Triton X-100 buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4, 1% Triton X-100). Samples were spun at 12 000 g for 10 min at 4 C, and the pellet was removed. The supernatant was precleared with 100 ml of Dynabeads Protein G/1 ml sample (Invitrogen, #100.041) and pre-immune mouse IgG (Active Motif, #101226), on a rotator for 1 h at 4 C at 15 rpm.
Beads were removed with a magnet, and mouse anti-NP1 primary antibody (BD Transduction Labs, #610369) was incubated in the sample overnight at 10 lg/ll sample. Dynabeads Protein G were added to the sample at 200 ll/ml sample and incubated on a rotator for 1 h at 4 C at 15 rpm. The Dynabeads Protein G were isolated via magnet and the supernatant removed. Samples were washed 5 times with 1 ml lysis buffer, and then suspended in Laemmli sample buffer. Samples were heated at 65 C for 20 min, Dynabeads Protein G were removed and the samples underwent SDS-PAGE and western blotting on PVDF, followed by staining with a mouse anti-NP1 primary antibody (BD Transduction Labs, #610369) followed by secondary goat anti-mouse (Santa Cruz Biotechnology, sc-2005) IgG-HRP conjugated antibodies (see Western blot).
, and Np1
were observed at intervals no greater than 7 days, beginning at $7 weeks of age (before the detriments are normally observed in SD mice), until endpoint was reached (i.e. mouse can no longer right self in <45 s on each side). Measurements were taken of bodyweight, lifespan, righting reflex, wire hang, and rotarod tests. Righting Reflex: Mice were positioned on their backs (with a slight tilt to the left and then repeated to the right) on a solid surface, and time for mouse to right itself onto its feet was measured. The average of measurements for the left side and right side righting reflex was used a measurement of cerebellar function/proprioception. Endpoint was reached when mice could not right themselves for two consecutive days on both the right and left sides. Survival: Lifespan was measured from date of birth until endpoint measured by righting reflex as described earlier.
Wire Hang: Mice were placed on top of a wire mesh, which was then inverted, 30 cm above a padded surface. Hang time was measured from the point of inversion, until time to fall-to a maximum of 5 min. The best time of three consecutive trials was used. Rotarod: Mice were placed on a rotating rod (Accuscan EzRod with EzRod v.120 software), and time to fall was measured via photo-sensors. Rotarod rotations were increased from 0 rpm to a maximum of 40 rpm over 360 s. Mice were placed on the rod at 4 rpm. The best time of three consecutive trials was used. Body masses were recorded from another cohort of mice (ages 60-120 days of age for Hexb Immunohistochemistry
, and Np1 À/À Hexb À/À mice were processed as previously described (14) . Mice were harvested at 17 weeks of age, perfused with PBS, fixed with 3.7% formaldehyde, and embedded in paraffin wax. Five-micrometre thick coronal cerebellar and cerebral cortex sections were sliced, and mounted on glass slides. The samples were then subjected to a xylene/ethanol/water rehydration series. Endogenous peroxidase was quenched with 1% H 2 O 2 . Samples to be stained for MAC3 underwent microwave antigen retrieval in 12 mM citric acid buffer. Samples were blocked with 10% goat serum, and immunolabeled with monoclonal antibodies against GFAP (Sigma-Aldrich, G3893), and MAC3 (BD Pharmingen, 553322). Tissues were then incubated with biotinylated secondary antibodies, followed by an avidin/HRP-bound biotin solution (Santa Cruz, Mouse ABC Staining System #sc-2017, Rat ABC Staining System #sc-2019). Samples were then stained with 3,3 0 -diaminobenzadine in the presence of 0.01% H 2 O 2 , and counterstained with methylene blue. For each slide, 10 random field images of the cerebellum and cerebral cortex were captured at 400Â magnification, centred on the Perkinje layer. The areas of the images were calculated using AxioVision 4.9.1 software (Zeiss, Oberkochen, Germany). For each sample, positively stained cells microglia/macrophages and astrocytes were quantified as the total count per 10 random fields/ total area of the 10 fields.
Tunel
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed as previously described on formalinfixed, paraffin-embedded cerebellar, cerebral cortex and spinal tissues, according to manufacturer's instructions using the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Millipore, #S7100) (14) . Sections were subjected to a xylene/ethanol rehydration series, and then with proteinase K for 10 min. After blocking endogenous peroxides activity with 3% hydrogen peroxide, the samples were incubated with terminal deoxynucleotidyl transferase (TdT) enzyme at 37 NMDG-aCSF was used for slicing and recovery. Transverse slices containing the hippocampus were obtained at 300 mm using a vibrating microtome. Slices were allowed to recover for 1 h at 37 C in an oxygenated, humidified interface chamber before being transferred to a recording chamber and continuously perfused with oxygenated recording aCSF solution (32-35 C in bath) containing, in mM: NaCl, 124; KCl, 2.5; NaH 2 PO 4 , 1.2; NaHCO 3 , 24; HEPES, 5; Glucose, 12.5; MgSO 4 , 2; CaCl 2 , 2; 300-310 mOsm; pH 7.3-7.4 adjusted with 7NaOH or HCl. A borosilicate glass stimulating electrode (1 MX) containing aCSF recording solution was placed in the CA3-CA1 pathway. CA1 pyramidal cells were identified, using IR-DIC optics, by morphology and position within the hippocampus. Whole-cell patch recordings were made using borosilicate glass patch pipettes (1.5-2.5 MX) filled with internal solution containing, in mM: D-gluconic acid, 64; CsOH, 64; EGTA, 11; CsCl, 56; MgCl, 1; CaCl 2 , 1; HEPES, 10; GTP-Na, 0.3; ATP-Mg, 4; QX-314, 5. Series resistance was compensated (80%) and the seal monitored throughout the experiment, and recordings were aborted if input resistance was >150 MX or access resistance exceeded 25 MX or changed >15%. GABAergic responses were inhibited by addition of the GABA receptor antagonist picrotoxin (50 mM) to the perfusate, and pyramidal neurons of the CA1 region of the hippocampus were voltage-clamped at þ40 mV to measure total glutamate currents, and at À60 mV to measure the contribution of AMPA receptor currents. Specificity of the glutamate currents was confirmed by bath application of the NMDA and AMPA receptor antagonists D-APV (50 mM) and CNQX (5 mM). To guard against possible bias, slice preparation, electrophysiological recording, and analysis were all performed by an experimenter blind to genotype. To account for pseudoreplicates, the measurements for each individual animal were averaged, and then statistics were performed by animal, rather than by neuron (49, 50) .
Statistical software
For data sets with two groups, t-tests were used to test for differences between means at P < 0.05. For data sets with three or more groups, one-way ANOVA was used to test for differences between means at P < 0.05. ANOVA was followed by Tukey's post hoc for all data with high normality and equal variance amongst groups. For groups of unequal variance, Dunnett's T3 test was used for pairwise comparison. For Samples with unequal variance and unequal sample sizes, Kruskal-Wallis test was used for pairwise comparison. Equality of variances was calculated with Levene's test. All statistical analyses were performed using SPSS v16 (SPSS Inc. Chicago, IL).
